MRNA supply chain intelligence for Moderna, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ARBUTUS | ARBUTUS | 90% | Third-party royalties included $878 million related to the litigation settlement with Arbutus and Genevant, as well as amortization of the associated intangible asset. |
| ARBUTUS-GENEVANT | ARBUTUS-GENEVANT | 90% | The Settlement Agreement includes a fully paid-up, royalty free, irrevocable, non-exclusive, worldwide license and covenant not to sue granted by Arbutus/Genevant to Moderna |
| GENEVANT | GENEVANT | 90% | Third-party royalties included $878 million related to the litigation settlement with Arbutus and Genevant, as well as amortization of the associated intangible asset. |
| CARISMA-THERAPEUTICS | CARISMA-THERAPEUTICS | 85% | We have entered into additional collaborations where we have agreed to provide funding in areas where we believe we can leverage our mRNA technology. These collaborations include those with: • Carism… |
| CYTOMX-THERAPEUTICS | CYTOMX-THERAPEUTICS | 85% | We have entered into additional collaborations where we have agreed to provide funding in areas where we believe we can leverage our mRNA technology. These collaborations include those with: • CytomX… |
| NATIONAL-INSTITUTE-OF-ALLERGY-AND-INFECTIOUS-DIS | NATIONAL-INSTITUTE-OF-ALLERGY-AND-INFECTIOUS-DIS | 80% | In December 2022, we entered into a non-exclusive patent license agreement with the National Institute of Allergy and Infectious Diseases (NIAID) |
| IMTX | Immatics N.V. | 72% | Reciprocal relationship from IMTX graph: Reciprocal relationship from MRNA graph: tablished a global Environment, Health, and Safety (EHS) organization to foster a safe and healthy work environment w… |
| IMTX | Immatics N.V. | 72% | tablished a global Environment, Health, and Safety (EHS) organization to foster a safe and healthy work environment with a focus on sustainability and compliance. Our approach integrates environmenta… |
| SNYNF | Sanofi | 72% | at leads to shareholder value, broad eligibility for our equity programs further embeds our "We behave like owners" mindset and helps promote employee retention as these awards generally vest over a … |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from MRNA graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from MRNA graph: Reciprocal relationship from SNYN… |
| VRTX | Vertex Pharmaceuticals Incorporated | 72% | Reciprocal relationship from VRTX graph: Reciprocal relationship from MRNA graph: tablished a global Environment, Health, and Safety (EHS) organization to foster a safe and healthy work environment w… |
| VRTX | Vertex Pharmaceuticals Incorporated | 72% | tablished a global Environment, Health, and Safety (EHS) organization to foster a safe and healthy work environment with a focus on sustainability and compliance. Our approach integrates environmenta… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| VERTEX-PHARMACEUTICALS-INCORPORATED | VERTEX-PHARMACEUTICALS-INCORPORATED | 92% | In July 2016, we entered into a Strategic Collaboration and License Agreement (Vertex Agreement) with Vertex Pharmaceuticals Incorporated |
| VRTX | Vertex Pharmaceuticals Incorporated | 92% | Reciprocal relationship from VRTX graph: Reciprocal relationship from MRNA graph: Reciprocal relationship from VRTX graph: Reciprocal relationship from MRNA graph: Reciprocal relationship from VRTX g… |
| FOREIGN-GOVERNMENTS | FOREIGN-GOVERNMENTS | 90% | We sell our COVID vaccines, Spikevax and mNEXSPIKE, to the commercial market as well as to foreign governments and international organizations. |
| INTERNATIONAL-ORGANIZATIONS | INTERNATIONAL-ORGANIZATIONS | 90% | We sell our COVID vaccines, Spikevax and mNEXSPIKE, to the commercial market as well as to foreign governments and international organizations. |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from MRNA graph: Reciprocal relationship from AZN graph: Reciprocal relationship from MRNA graph: Reciprocal relationship from AZN grap… |
| AZN | AstraZeneca PLC | 72% | sease in birds known as avian influenza and poses a risk of spillover into the human population. The agreement also includes additional options to prepare for and accelerate responses to future publi… |
| IMTX | Immatics N.V. | 72% | er the greatest possible impact to people through mRNA medicines. COMMERCIAL We continue to build our differentiated commercial model, with active commercial subsidiaries in key markets across North … |
| IMTX | Immatics N.V. | 72% | Reciprocal relationship from IMTX graph: Reciprocal relationship from MRNA graph: er the greatest possible impact to people through mRNA medicines. COMMERCIAL We continue to build our differentiated … |
| MRK | Merck & Co., Inc. | 72% | ics. Among all variables, estimating returns continues to present the most significant judgment due to the broad range of potential outcomes and the lack of established return trends. While we now ha… |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from MRNA graph: Reciprocal relationship from MRK graph: Reciprocal relationship from MRNA graph: Reciprocal relationship from MRK grap… |
| SNYNF | Sanofi | 72% | ms are unsuccessful, or not as successful as others could have been, we may be unable to realize a sustainable return on our investments and or achieve long-term growth. The vaccine market, and pharm… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from MRNA graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from MRNA graph: ms are unsuccessful, or not as su… |
| VRTX | Vertex Pharmaceuticals Incorporated | 72% | ics. Among all variables, estimating returns continues to present the most significant judgment due to the broad range of potential outcomes and the lack of established return trends. While we now ha… |
| AI-TECHNOLOGIES | AI-TECHNOLOGIES | 62% | ully complied, with such laws, we could face substantial penalties. Healthcare providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendatio… |
| GENERATION-BIO-CO | GENERATION-BIO-CO | 62% | possible impact to people through mRNA medicines. COMMERCIAL We continue to build our differentiated commercial model, with active commercial subsidiaries in key markets across North America, Europe … |
| TAKEDA-PHARMACEUTICAL-COMPANY | TAKEDA-PHARMACEUTICAL-COMPANY | 62% | ncial institution. Bank accounts in the United 109 States are insured by the Federal Deposit Insurance Corporation (FDIC) up to $250,000. Our primary operating accounts significantly exceed the FDIC … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| MRNA-DEBT | Debt stack $1.3B | 90% | Market cache reports total debt of $1.3B. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| MRNA-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 741 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| CCCC | C4 Therapeutics, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| EVH | Evolent Health, Inc. | 100.00 | 2 | |
| FIP | FTAI Infrastructure Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| CRBP | Corbus Pharmaceuticals Holdings, Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| IMMP | Immutep Limited | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 |